LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Search

ADMA Biologics Inc

Geschlossen

Branche Gesundheitswesen

16.26 -2.75

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.23

Max

16.37

Schlüsselkennzahlen

By Trading Economics

Einkommen

35M

18M

Verkäufe

8M

82M

EPS

0.08

Gewinnspanne

21.748

Angestellte

624

EBITDA

7.9M

24M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+18.88 upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-163M

4B

Vorheriger Eröffnungskurs

19.01

Vorheriger Schlusskurs

16.26

Nachrichtenstimmung

By Acuity

50%

50%

114 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

ADMA Biologics Inc Chart

Ähnliche Nachrichten

6. Sept. 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6. Sept. 2024, 21:18 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6. Sept. 2024, 21:05 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6. Sept. 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. Sept. 2024, 20:39 UTC

Ergebnisse

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6. Sept. 2024, 20:35 UTC

Top News

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6. Sept. 2024, 20:34 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6. Sept. 2024, 20:11 UTC

Top News

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6. Sept. 2024, 19:51 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6. Sept. 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6. Sept. 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6. Sept. 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6. Sept. 2024, 18:27 UTC

Top News

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6. Sept. 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6. Sept. 2024, 18:15 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6. Sept. 2024, 18:12 UTC

Top News

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6. Sept. 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6. Sept. 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6. Sept. 2024, 17:30 UTC

Top News

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6. Sept. 2024, 17:27 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6. Sept. 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. Sept. 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6. Sept. 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6. Sept. 2024, 16:35 UTC

Ergebnisse
Heiße Aktien

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6. Sept. 2024, 16:33 UTC

Akquisitionen, Fusionen, Übernahmen

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6. Sept. 2024, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

6. Sept. 2024, 16:20 UTC

Ergebnisse

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6. Sept. 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. Sept. 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Sept. 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

ADMA Biologics Inc Prognose

Kursziel

By TipRanks

18.88% Vorteil

12-Monats-Prognose

Durchschnitt 19.33 USD  18.88%

Hoch 20 USD

Tief 18 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ADMA Biologics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

16.06 / 17.46Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

114 / 365 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.